Omalizumab demonstrates efficacy and safety in Chinese children under 12 with chronic urticaria: a case series
Abstract
Background Omalizumab, an anti-IgE antibody, is recommended as a second-line therapy for chronic spontaneous urticaria in patients aged ≥12 years; however, real-world evidence for its use in younger Chinese children remains limited. Therefore, this study aimed to evaluate its clinical efficacy, safety, and associated characteristics of omalizumab in this underserved pediatric population under 12 years of age. Methods We conducted a retrospective analysis of 13 Chinese children (aged
Fields of Study & Subjects
Urticaria and Related Conditions
Coagulation
Bradykinin
Polyphosphates
and Angioedema
Drug-Induced Adverse Reactions
Publication details
- Journal / source
- Frontiers in Pediatrics
- Publisher
- Frontiers Media SA
- Volume
- 14
- Pages
- 1815987–1815987
- Publication date
- 21 April 2026
- Language
- EN